ALMKT:EPA
Mauna Kea Technologies SA
€0.098
arrow_upward
+1.24%(+0.0012) 1D
Oct 29, 9:09:16 AM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALMKT...
Open
€0.10
High
€0.10
Low
€0.10
Mkt. cap
18.85M
Avg. vol.
470.68K
Volume
98.31K
P/E ratio
0.83
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
Open
€0.10
High
€0.10
Low
€0.10
Mkt. cap
18.85M
Avg. vol.
470.68K
Volume
98.31K
P/E ratio
0.83
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
News stories
From web sources and news partners
BigGo Finance
·
39 minutes ago
S&P 500 Valuations Near Dot-Com Peak as Yield-Curve Signal Stays Quiet
TradingView
·
1 hour ago
SPX: S&P 500 Futures Slip After Google’s Earnings Spoil the Mood Globally
FXLeaders
·
1 hour ago
Dow Futures Steady at 52.8K as JPMorgan, Caterpillar, UnitedHealth Signal Margin Stability
Yahoo Finance
·
10 hours ago
Semiconductor stocks lose momentum as S&P 500 takes lead
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA